SCHEMBL3606683

SCHEMBL3606683

N=C(N)Nc1nc(-c2cccc(C(=O)O)c2)cs1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSNK2A1 P68400 6/20 0.58
NPC1 O15118 2/20 0.57
MAPT P10636 2/20 0.57
RAB9A P51151 2/20 0.57
GAA P10253 1/20 0.57
NPSR1 Q6W5P4 1/20 0.57
CSNK2A2 P19784 1/20 0.56
CSNK2B P67870 1/20 0.56
CSNK2A3 Q8NEV1 1/20 0.56
ABL1 P00519 2/20 0.53
MEN1 O00255 1/20 0.53
KMT2A Q03164 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
SCD O00767 1/20 0.53
KDM4A O75164 1/20 0.53
KDM4B O94953 1/20 0.53
KDM5C P41229 1/20 0.53
KDM5B Q9UGL1 1/20 0.53
RRM1 P23921 1/20 0.53
RRM2B Q7LG56 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL7142457 0.99 CSNK2A1 (0.57) CSNK2A1NPC1MAPTRAB9AGAA
SCHEMBL3603750 0.91 MAPT (0.55) CSNK2A1NPC1MAPTRAB9AGAA
SCHEMBL11090239 0.88 MAPT (0.51) NPC1MAPTRAB9AGAANPSR1
SCHEMBL11091588 0.88 MAPT (0.55) NPC1MAPTRAB9AGAANPSR1
SCHEMBL11087776 0.86 ALDH1A1 (0.56) CSNK2A1NPC1MAPTRAB9AGAA
SCHEMBL3609767 0.86 PHGDH (0.55) NPC1MAPTRAB9AGAANPSR1
SCHEMBL11090908 0.85 MAPT (0.50) NPC1MAPTRAB9AGAANPSR1
SCHEMBL3615155 0.85 ALOX5 (0.51) NPC1MAPTRAB9AGAANPSR1
SCHEMBL11093012 0.85 GAA (0.48) CSNK2A1NPC1MAPTRAB9AGAA
SCHEMBL11093016 0.85 MAPT (0.48) NPC1MAPTRAB9AGAANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100298340-A1 Thiazol-Guanidine Derivatives Useful As A (Beta)-Related Pathologies ASTRAZENECA AB (SE) 2010-11-25 US claimed
EP-2010508-A1 THIAZOL-GUANIDINE DERIVATIVES USEFUL AS A (BETA)- RELATED PATHOLOGIES AstraZeneca AB (SE) 2009-01-07 EP claimed
WO-2007120096-A1 THIAZOL-GUANIDINE DERIVATIVES USEFUL AS A (BETA)- RELATED PATHOLOGIES ASTRAZENECA AB (SE) 2007-10-25 WO claimed
US-20100298340-A1 Thiazol-Guanidine Derivatives Useful As A (Beta)-Related Pathologies ASTRAZENECA AB (SE) 2010-11-25 US disclosed
EP-2010508-A1 THIAZOL-GUANIDINE DERIVATIVES USEFUL AS A (BETA)- RELATED PATHOLOGIES AstraZeneca AB (SE) 2009-01-07 EP disclosed
WO-2007120096-A1 THIAZOL-GUANIDINE DERIVATIVES USEFUL AS A (BETA)- RELATED PATHOLOGIES ASTRAZENECA AB (SE) 2007-10-25 WO disclosed
US-4452985-A 2-Guanyl-4-(substituted phenyl) thiazole derivatives AMERICAN HOME PRODUCTS CORPORATION (US) 1984-06-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298340-A1 Thiazol-Guanidine Derivatives Useful As A (Beta)-Related Pathologies GRN, MAPT, GUCY1B1 CSNK2A1 1563/4885NPC1 267/4885MAPT 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.